2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2579

Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2678

EULAR Primary SjöGren’s Syndrome Disease Activity Index (ESSDAI), Results from the National Registry of the Spanish Society of Rheumatology (SJÖGRENSER)

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2727

Evaluating Psoriatic Arthritis and Psoriasis Skin Lesions: Ultrasound As a Complementary Measure

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2323

Evaluation of Case-Finding Algorithms for Identification of Patients with Dermatomyositis

Muscle Biology, Myositis and Myopathies - Poster II: Clinical

9:00AM-11:00AM: Abstract Number: 2382

Evaluation of Intestinal Inflammation in Children with FMF

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

9:00AM-11:00AM: Abstract Number: 2451

Evaluation of Ovarian Reserve and Function in Adolescent Females with Systemic Lupus Erythematosus

Reproductive Issues in Rheumatic Disorders - Poster

9:00AM-11:00AM: Abstract Number: 2664

Evaluation of Thyroid Autoimmune Disease in Primary SjöGren’s Syndrome and Its Association with Disease Phenotype

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2184

Evidence Based Physical Activity Threshold to Predict Improved/High Function in Older Adults with Lower Extremity Conditions: The Osteoarthritis Initiative

Epidemiology and Public Health - Poster III

9:00AM-11:00AM: Abstract Number: 2274

Evidence of Phospho-Degron Regulating Expression of Urate Secretory Transporter ABCG2

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2693

Evolution of Disease Activity over a 5-Year Period in the 395 Patients with Primary SjöGren’s Syndrome of the Assess Prospective Cohort

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2722

Evolution over Thirty Years of the Profile of Inpatients with Reactive Arthritis in a Tertiary Rheumatology Unit

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2860

Exercise Significantly Improves Cardiorespiratory Fitness and Reduces Disease-Related Fatigue without Adverse Effects on Disease Activity in Systemic Lupus Erythematosus: a Systematic Review with Meta-Analysis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - ARHP Poster

9:00AM-11:00AM: Abstract Number: 2277

Exon Sequencing Reveals a Significant Burden of Non-Synonymous Variants in Both SLC22A11 (OAT4) and SLC22A12 (URAT1) in European Hyperuricemic Individuals

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2114

Exposure to Carbamylated Self- and Non-Self-Proteins Can Lead to a Break-of -Tolerance and the Induction of Autoimmunity

B Cell Biology and Targets in Autoimmune Disease - Poster II: Rheumatoid Arthritis and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2885

Expression Levels and Function of the Inhibitory Molecule, Immunoglobulin like Transcript 7 (ILT7), Are Decreased on Circulating Plasmacytoid Dendritic Cells in SLE Patients with High ANA Titers

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].